What is the Fiscal Year for NeuroSense Therapeutics?
Date: November 13, 2026
NeuroSense Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Cambridge, Massachusetts
Industry
Biotechnology Research
Stock Symbol
NRSN
Website
https://neurosense-tx.comDescription
Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally. $NRSN
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like NeuroSense Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.